Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 8/20 | 0.58 |
| ▸ | DRD4 | P21917 | 8/20 | 0.58 |
| ▸ | HTR1A | P08908 | 4/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.58 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 2/20 | 0.47 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16480406 | 0.89 | HDAC6 (0.51) | DRD2HTR1ACHRM4HDAC6ADRB1 | |
| SCHEMBL9893124 | 0.87 | HDAC6 (0.52) | DRD2DRD4HTR1AKCNH2CHRM4 | |
| SCHEMBL1729313 | 0.78 | PKM (0.55) | DRD2HTR1ACHRM4HDAC6ADRB1 | |
| SCHEMBL19652155 | 0.76 | ADRB1 (0.51) | KCNH2CHRM4ADRB1PKMSLC6A7 | |
| SCHEMBL9108822 | 0.76 | ADRB1 (0.59) | HTR1AHDAC6ADRB1PKMSLC6A7 | |
| SCHEMBL9108819 | 0.76 | PARP1 (0.56) | HTR1ACHRM4HDAC6ADRB1PKM | |
| SCHEMBL8354208 | 0.75 | ADRB1 (0.78) | HTR1AHDAC6ADRB1PKMSLC6A7 | |
| SCHEMBL3986386 | 0.75 | ADRB1 (0.58) | DRD2HTR1AHDAC6ADRB1PKM | |
| SCHEMBL9891947 | 0.74 | CHRM4 (0.48) | DRD2DRD4HTR1ACHRM4HDAC6 | |
| SCHEMBL12969642 | 0.74 | ADRB1 (0.68) | ADRB1PKMSLC6A7CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8629157-B2 | Pyrrolidine compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-14 | — | — | US | disclosed |
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | DRD2 246/4885DRD4 443/4885HTR1A 346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.